Spastisitet etter ryggmargsskade

Tidsskrift for den Norske Laegeforening

Volumn 132, Issue 8, 2012, Pages 970-973

  Rekand, Tiina ^a   Hagen, Ellen Merete ^a   Grønning, Marit ^a,b  

^a HAUKELAND UNIVERSITY HOSPITAL   (Norway)

^b UNIVERSITY OF BERGEN   (Norway)

Author keywords

[No Author keywords available]

Indexed keywords

BACLOFEN; BOTULINUM TOXIN; CENTRAL MUSCLE RELAXANT;

CLINICAL PATHWAY; HUMAN; INTRAMUSCULAR DRUG ADMINISTRATION; INTRASPINAL DRUG ADMINISTRATION; ORAL DRUG ADMINISTRATION; PARALYSIS; PATHOPHYSIOLOGY; REVIEW; SEVERITY OF ILLNESS INDEX; SPASTICITY; SPINAL CORD INJURY;

ADMINISTRATION, ORAL; BACLOFEN; BOTULINUM TOXINS; CRITICAL PATHWAYS; HUMANS; INFUSIONS, SPINAL; INJECTIONS, INTRAMUSCULAR; MUSCLE RELAXANTS, CENTRAL; MUSCLE SPASTICITY; PARALYSIS; SEVERITY OF ILLNESS INDEX; SPINAL CORD INJURIES;

EID: 84865281606     PISSN: 00292001     EISSN: 08077096     Source Type: Journal    
DOI: 10.4045/tidsskr.10.0872     Document Type: Article

References (43)

1. Johnson RL, Gerhart KA, McCray J et al. Secondary conditions following spinal cord injury in a population-based sample. Spinal Cord 1998; 36: 45-50.
2. Noreau L, Proulx P, Gagnon L et al. Secondary impairments after spinal cord injury: a populationbased study. Am J Phys Med Rehabil 2000; 79: 526-35.
3. Levi R, Hultling C, Nash MS et al. The Stockholm spinal cord injury study: 1. Medical problems in a regional SCI population. Paraplegia 1995; 33: 308-15.
4. Sköld C, Levi R, Seiger Å. Spasticity after traumatic spinal cord injury: nature, severity, and location. Arch Phys Med Rehabil 1999; 80: 1548-57.
5. Lance JW. The control of muscle tone, reflexes, and movement: Robert Wartenberg Lecture. Neurology 1980; 30: 1303-13.
6. Stevenson VL. Rehabilitation in practice: Spasticity management. Clin Rehabil 2010; 24: 293-304.
7. Ward AB. Spasticity treatment with botulinum toxins. J Neural Transm 2008; 115: 607-16.
8. Elbasiouny SM, Moroz D, Bakr MM et al. Management of spasticity after spinal cord injury: current techniques and future directions. Neurorehabil Neural Repair 2010; 24: 23-33.
9. Saval A, Chiodo AE. Intrathecal baclofen for spasticity management: a comparative analysis of spasticity of spinal vs cortical origin. J Spinal Cord Med 2010; 33: 16-21.
10. Gracies J-M. Pathophysiology of spastic paresis. I: Paresis and soft tissue changes. Muscle Nerve 2005; 31: 535-51.
11. Gracies J-M. Pathophysiology of spastic paresis. II: Emergence of muscle overactivity. Muscle Nerve 2005; 31: 552-71.
12. Adams MM, Hicks AL. Spasticity after spinal cord injury. Spinal Cord 2005; 43: 577-86.
13. Green D, Hartwig D, Chen D et al. Spinal Cord Injury Risk Assessment for Thromboembolism (SPIRATE Study). Am J Phys Med Rehabil 2003; 82: 950-6.
14. Murphy NA. Deep venous thrombosis as a result of hypotonia secondary to intrathecal baclofen therapy: a case report. Arch Phys Med Rehabil 2002; 83: 1311-2.
15. Yelnik AP, Simon O, Parratte B et al. How to clinically assess and treat muscle overactivity in spastic paresis. J Rehabil Med 2010; 42: 801-7.
16. Lechner HE, Frotzler A, Eser P. Relationship between self- and clinically rated spasticity in spinal cord injury. Arch Phys Med Rehabil 2006; 87: 15-9.
17. Ashworth B. Preliminary trial of carisopodol in multiple sclerosis. Practitioner 1964; 192: 540-2.
18. Fleuren JF, Voerman GE, Erren-Wolters CV et al. Stop using the Ashworth Scale for the assessment of spasticity. J Neurol Neurosurg Psychiatry 2010; 81: 46-52.
19. Tardieu G, Shentoub S, Delarue R. A la recherché d'une technique de mesure de la spasticité. Rev Neurol 1954; 91: 143-4.
20. Mehrholz J, Wagner K, Meissner D et al. Reliability of the Modified Tardieu Scale and the Modified Ashworth Scale in adult patients with severe brain injury: a comparison study. Clin Rehabil 2005; 19: 751-9.
21. Penn RD, Savoy SM, Corcos D et al. Intrathecal baclofen for severe spinal spasticity. N Engl J Med 1989; 320: 1517-21.
22. Priebe MM, Sherwood AM, Thornby JI et al. Clinical assessment of spasticity in spinal cord injury: a multidimensional problem. Arch Phys Med Rehabil 1996; 77: 713-6.
23. Gracies JM. Pathophysiology of impairment in patients with spasticity and use of stretch as a treatment of spastic hypertonia. Phys Med Rehabil Clin N Am 2001; 12: 747-68.
24. Kita M, Goodkin DE. Drugs used to treat spasticity. Drugs 2000; 59: 487-95.
25. Hinderer SR, Lehmann JF, Price R et al. Spasticity in spinal cord injured persons: quantitative effects of baclofen and placebo treatments. Am J Phys Med Rehabil 1990; 69: 311-7
26. Burke D, Gillies JD, Lance JW. An objective assessment of a gamma aminobutyric acid derivative in the control of spasticity. Proc Aust Assoc Neurol 1971; 8: 131-4.
27. Dario A, Tomei G. A benefit-risk assessment of baclofen in severe spinal spasticity. Drug Saf 2004; 27: 799-818.
28. Milanov I, Georgiev D. Mechanisms of tizanidine action on spasticity. Acta Neurol Scand 1994; 89: 274-9.
29. Nance PW, Bugaresti J, Shellenberger K et al. Efficacy and safety of tizanidine in the treatment of spasticity in patients with spinal cord injury. Neurology 1994; 44 (suppl 9): S44-51.
30. Taricco M, Pagliacci MC, Telaro E et al. Pharmacological interventions for spasticity following spinal cord injury: results of a Cochrane systematic review. Eura Medicophys 2006; 42: 5-15.
31. Karst M, Wippermann S, Ahrens J. Role of cannabinoids in the treatment of pain and (painful) spasticity. Drugs 2010; 70: 2409-38.
32. Müller K, Mix E, Adib Saberi F et al. Prevalence of neutralising antibodies in patients treated with botulinum toxin type A for spasticity. J Neural Transm 2009; 116: 579-85.
33. Wissel J, Ward AB, Erztgaard P et al. European consensus table on the use of botulinum toxin type A in adult spasticity. J Rehabil Med 2009; 41: 13-25.
34. Giovannelli M, Borriello G, Castri P et al. Early physiotherapy after injection of botulinum toxin increases the beneficial effects on spasticity in patients with multiple sclerosis. Clin Rehabil 2007; 21: 331-7.
35. Smedal T, Gjelsvik B, Lygren H et al. Botulinum toksin A- effekt på spastisitet. Tidsskr Nor Lægeforen 2001; 121: 3277-80.
36. Naumann M, Albanese A, Heinen F et al. Safety and efficacy of botulinum toxin type A following long-term use. Eur J Neurol 2006; 13 (suppl 4): 35-40.
37. Marciniak C, Rader L, Gagnon C. The use of botulinum toxin for spasticity after spinal cord injury. Am J Phys Med Rehabil 2008; 87: 312-7, quiz 318-20, 329.
38. Coffey JR, Cahill D, Steers W et al. Intrathecal baclofen for intractable spasticity of spinal origin: results of a long-term multicenter study. J Neurosurg 1993; 78: 226-32.
39. Koulousakis A, Kuchta J. Intrathecal antispastic drug application with implantable pumps: results of a 10 years follow-up study. Acta Neurochir Suppl (Wien) 2007; 97: 181-4.
40. Guillaume D, Van Havenbergh A, Vloeberghs M et al. A clinical study of intrathecal baclofen using a programmable pump for intractable spasticity. Arch Phys Med Rehabil 2005; 86: 2165-71.
41. Lynn AK, Turner M, Chambers HG. Surgical management of spasticity in persons with cerebral palsy. PM R 2009; 1: 834-8.
42. Smyth MD, Peacock WJ. The surgical treatment of spasticity. Muscle Nerve 2000; 23: 153-63.
43. Grønning M, Svendsen F, Skeidsvoll H et al. Spastisitet behandlet med selektiv bakre rhizotomi. Tidsskr Nor Lægeforen 2002; 122: 1190-1.